Baseline patient characteristics
| Variables | All patients (n=123) | LV remodelling (n=16) | No LV remodelling (n=107) | p Value |
|---|---|---|---|---|
| Age, years | 57±11 | 60±11 | 57±10 | 0.24 |
| Male sex, n (%) | 108 (88) | 12 (75) | 96 (90) | 0.09 |
| Body mass index, kg/m2 | 26 (25–28) | 27 (25–30) | 26 (25–28) | 0.52 |
| Cardiovascular risk factors | ||||
| Hypertension, n (%) | 77 (63) | 12 (75) | 65 (61) | 0.27 |
| Diabetes mellitus, n (%) | 10 (8) | 0 (0) | 10 (9) | 0.20 |
| Current smoker, n (%) | 63 (51) | 7 (44) | 56 (52) | 0.52 |
| Hypercholesterolaemia, n (%) | 78 (63) | 8 (50) | 70 (65) | 0.23 |
| Family history for AMI, n (%) | 35 (29) | 4 (25) | 31 (29) | 0.74 |
| Pain-to-balloon time, min | 192 (137–352) | 214 (132–421) | 192 (137–351) | 0.87 |
| Infarct-related artery | 0.03 | |||
| Right coronary artery, n (%) | 58 (47) | 5 (31) | 53 (49) | |
| Left anterior descending artery, n (%) | 50 (41) | 11 (69) | 39 (36) | |
| Left circumflex coronary artery, n (%) | 15 (12) | 0 (0) | 15 (14) | |
| Number of diseased vessels | 0.09 | |||
| 1, n (%) | 64 (52) | 9 (56) | 55 (51) | |
| 2, n (%) | 44 (36) | 3 (18) | 41 (38) | |
| 3, n (%) | 15 (12) | 4 (25) | 11 (10) | |
| Medication at discharge | ||||
| Acetylsalicylic acid, n (%) | 123 (100) | 16 (100) | 107 (100) | 1.0 |
| β-Blocker, n (%) | 104 (85) | 14 (87) | 90 (84) | 0.99 |
| ACE-I or ARB, n (%) | 105 (86) | 14 (87) | 91 (85) | 0.41 |
| Statin, n (%) | 117 (95) | 16 (100) | 101 (94) | 0.57 |
| Admission NT-proBNP, ng/L | 100 (58–401) | 125 (63–838) | 99 (54–371) | 0.44 |
| Admission hs-cTnT, ng/L | 144 (21–1835) | 132 (18–10 263) | 153 (25–1617) | 0.58 |
| Admission AST, U/L | 74 (33–223) | 97 (36–410) | 73 (33–213) | 0.55 |
| Admission ALT, U/L | 37 (27–65) | 37 (28–90) | 36 (27–65) | 0.50 |
| Admission LDH, U/L | 237 (196–343) | 241 (204–586) | 234 (196–324) | 0.27 |
| Admission hs-CRP, mg/L | 2.1 (1.1–5.0) | 1.8 (1.1–3.6) | 2.1 (1.1–5.6) | 0.41 |
| Peak NT-proBNP, ng/L | 704 (196–1391) | 1385 (616–3949) | 677 (151–1267) | 0.02 |
| Peak hs-cTnT, ng/L | 5464 (2337–8574) | 10 153 (5722–15 995) | 4709 (1985–8025) | <0.01 |
| Peak AST, U/L | 245 (138–369) | 375 (240–646) | 231 (126–349) | <0.01 |
| Peak ALT, U/L | 57 (40–88) | 73 (49–141) | 52 (38–81) | 0.04 |
| Peak LDH, U/L | 593 (353–832) | 917 (654–1530) | 523 (324–791) | <0.01 |
| Peak hs-CRP, mg/L | 19.9 (9.2–44.4) | 31.8 (16.7–56.4) | 17.0 (9.0–38.8) | 0.08 |
Continuous variables are shown as mean±SD or as median plus IQR.
ACE-I, ACE inhibitors; ALT, alanine transaminase; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase; hs-CRP, high-sensitivity C reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; LDH, lactate dehydrogenase; LV, left ventricular; NT-proBNP, N-terminal pro B-type natriuretic peptide.